Navigation Links
Alfa in Medical News

Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann

NEW YORK, Aug. 4 /PRNewswire-FirstCall / -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) announced today that the Company and Alfa Wassermann S.p.A. have settled a dispute over issues arising from the terminated license agreement for Sulonex (sulodexide). Under the terms of the settl...

Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa

HORSHAM, Pa., May 13 /PRNewswire/ -- Data from a study of managed-care cancer patients receiving chemotherapy and newly treated with erythropoiesis-stimulating agents (ESAs) found that the cumulative ESA cost with Epoetin alfa (EPO) was 29 percent lower than treatment with darbepoetin alfa (DARB)....

Biogen Idec's baminercept alfa shows promise in patients with rheumatoid arthritis

Paris, France June 12, 2008 -- Biogen Idec will present data on baminercept alfa (BG9924, LTR-Ig), the first dual-mechanism, lymphotoxin-; (LT-;) and LIGHT pathway inhibitor in development for the treatment of autoimmune diseases, including rheumatoid arthritis (RA), during the 2008 European Leag...

Updated Analysis of 2001 Epoetin Alfa Study Posted

BRIDGEWATER, N.J., Dec. 4 /PRNewswire/ -- An updated analysis from a 2001 study conducted by the Gynecologic Oncology Group evaluating Epoetin alfa in 109 patients with cervical cancer has been posted online ( http://dx.doi.org/10.1016/j.ygyno.2007.10.011 ). The study (GOG-191) was terminated ...

Schering-Plough Announces European Submission of Fertility Medicine Corifollitropin Alfa

Corifollitropin alfa, a sustained follicle stimulant, extends options for patients and Schering-Plough's leadership in fertility KENILWORTH, N.J., Dec. 31 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE: SGP ), a leading provider of fertility treatments, announced today that the Euro...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

...E(R) for Patients with Mantle Cell Lymphoma II-44 4. Recent Industry Activity II-45 CytRx to Acquire Innovive II-45 Launch of Epoetin alfa Hexal II-45 PDL and Bristol-Myers Signs Agreement II-45 MNKD and LLS Conclude Joint Research Agreement II-45 MorphoSys and DSM Enter into ...

Calling All Aspiring Filmmakers! The In The Know Short Film Competition Announces Call for Entries Women and Couples Encouraged to Enter TODAY, Share Their Fertility Stories and Inspire Others

...ovided by EMD Serono, the company that brings you Gonal-f® (follitropin alfa for injection). EMD Serono is proud to announce that it will be donati... with infertility. Important Considerations: Gonal-f® (follitropin alfa for injection) is indicated for use in infertile patients with oligo-anovul...

Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking?

... (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alpha for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alpha injection). With a clear focus on the patient and a leadership presence in ...

Amgen Highlights Data to Be Presented at ASCO

... DAHANCA-10 Aranesp pharmacovigilance trial in head and neck cancer patients will be presented. Randomized study of darbepoetin alfa as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): Final outcome of the DAHANCA-10 trial ...

Senior Living Executives Optimistic About Future

...s say industry is weathering recession at national alfa conference PHILADELPHIA , May 7 /PRNewswire-...t a panel on the final day of the three day annual alfa Conference and Exposition at the Philadelphia Conv...ppeal to investors." Highlights from the 2009 alfa conference and expo can be found at www.alfa.org...
Alfa in Medical Technology

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

LEXINGTON, Massachusetts, August 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company, today reported positive results from the first of three Phase III studies of velaglucerase alfa, its enzyme replacement therapy in development fo...

Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease

LEXINGTON, Massachusetts, July 16 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company, announces it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for velaglucerase alfa, its enzyme replacement t...

Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease

LEXINGTON, Massachusetts, July 6 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company, announces that, at the request of the FDA, in view of a potential restriction on the availability of the current approved and marketed treatment fo...

Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma

HOUSTON, July 1 /PRNewswire/ -- Agennix Incorporated today announced the publication of final results from a Phase 2 monotherapy trial with talactoferrin alfa in patients who had failed previous treatment for advanced or metastatic renal cell carcinoma (RCC). Results from the study, which were...

Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting

Company Also Announces Receipt of Fast Track Designation from FDA, Favorable Scientific Advice from EMEA and Phase 3 Plans for the Non-Small Cell Lung Cancer Monotherapy Indication SANTA MONICA, Calif., Feb. 26 /PRNewswire/ -- Dr. Giuseppe Giaccone, Chief of the Medical Onco...

Preliminary Data From Experimental Study Demonstrate Increased Mortality in Stroke Patients Treated With Epoetin Alfa

BRIDGEWATER, N.J., Sept. 17 /PRNewswire/ -- Ortho Biotech has become aware of preliminary data from an investigator-initiated experimental study of the effects of Epoetin alfa in patients with acute ischemic stroke. In this study, patients suffering acute ischemic stroke who were treated with ...

Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target

OSS, the Netherlands, June 27, 2007-Organon, the human healthcare business unit of Akzo Nobel, announced today that two out of three Phase III clinical trials with corifollitropin alfa (Org 36286), a new long-acting fertility hormone, have reached their randomization target. Corifollitropin al...

Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma

... HOUSTON, May 19 /PRNewswire/ -- Agennix announced today that talactoferrin alfa (talactoferrin) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the first-line treatment of renal cell carc...

Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial

... was to assess whether Bronchitol further improves lung function in patients already being treated with the most commonly used CF therapeutic, dornase alfa (Pulmozyme(TM)). This endpoint was also successfully achieved. For patients being treated with concurrent dornase alfa, FEV1 improved after 6 months...

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

...Week 48 for ACHIEVE 2/3. About Albinterferon Alfa-2b (Albuferon) Albinterferon alfa-2b is a genetic fusion of human albumin and interferon alfa created using the proprietary HGS albumin-fusion technology. Human albumin is the most prevalent naturally occurring blood protein in the human circu...

More>>

Alfa in Medical Products

Oti Alfa Acetabular liners

Description: ...
Company:Encore Medical Corporation

Alfa Cluster

Description:... alfa acetabular cup system has been designed to enhance fixation in the acetabul...imize micromotion on three primary modes: Tilt, migration and rotation. The alfa systems advanced design features result in initial and long-term fixation. ...
Company:Encore Medical Corporation

Alfa Tri-Spike

Description:... alfa acetabular cup system has been designed to enhance fixation in the acetabul...imize micromotion on three primary modes: Tilt, migration and rotation. The alfa systems advanced design features result in initial and long-term fixation. ...
Company:Encore Medical Corporation
Alfa in Medical Dictionary

Genitourinary system

...ook brings together more than 100 internationally leading scientists to ... Microbiology of the Genitourinary System Allan Ross Ronald Michelle J. alfa ... ...

Alpha

...k alphabet. The first one; the beginning. Chemistry. ... Alpha supports both the OpenVMS (previously known as OpenVMS AXP) ... Alpha Look up alfa or alpha in Wiktionary , the free dictionary. ... Alpha channel, describing transparency and opacity in computer graphics ... Flight & Pil...
Alfa in Biological News

UV lotion lights the way to cleaner facilities

...ow that spores from the nasty bacteria Clostridium difficile (C. difficile) linger in the loo even when it has been thoroughly wiped down. Michelle alfa and a team of scientists from Manitoba, Canada investigated the spread of so-called superbugs in hospitals. Hospital patients are thought to catch bug...

Novel therapy combinations gain ground in treating hepatitis

...urvival." Comparison of Daily Consensus Interferon versus Peginterferon alfa 2a Extended Therapy of 72 Weeks for Peginterferon / Ribavirin Relapse Patie...sensus interferon) plus ribavirin (RBV) versus pegIFN (pegylated interferon alfa 2a) plus RBV for 72 weeks in patients with a prior relapse to 48 weeks of t...
Alfa in Biological Technology

Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer

Trial will also Support a Marketing Authorization Application in the European Union HOUSTON, Jan. 17 /PRNewswire/ -- Agennix Incorporated announced today that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase 3 trial e...

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa

Single-dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study AMSTERDAM, July 1 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE: SGP ) today announced results from the Phas...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

...impairment in depression. Velaglucerase alfa - for the treatment of Gaucher disease - On J... the rolling submission of a NDA for velaglucerase alfa to treat patients with Type 1 Gaucher diseas...mprovements in the primary endpoint. Velaglucerase alfa was also found to be well tolerated with no ...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... Early hemoglobin decline and survival prognosis in epoetin alfa studies (Abstract 9625) General Poster Session, Monday Jun...noncardiac, nonvascular surgery. Depending on the country in which Epoetin alfa is marketed, these indications may differ. Important Safety Informati...

Shire begins the year with a strong performance

...scents in the US in the fourth quarter of 2009; - DAYTRANA for the treatment of ADHD in adolescents in the US in 2010; - Velaglucerase alfa for the treatment of Gaucher disease in the US and the EU in 2010; and - VYVANSE for the treatment of ADHD, in ex-US and ex-EU regions star...

Publication of Shire plc's Annual Report 2008

...the US, including VYVANSE, DAYTRANA, velaglucerase alfa (GA-GCB), SPD550, PLICERA, AMIGAL, AT2220 and META... in Canada; and - the launch of Velaglucerase alfa in the EU. This program of new product lau...d quarter of 2009. ERT Velaglucerase alfa (GA-GCB) - for the treatment of Gaucher disease ...

Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion

... 2010; - VYVANSE (lisdexamfetamine dimesylate) for use in the treatment of ADHD in children in Canada during 2010; and - Velaglucerase alfa for the treatment of Gaucher disease in the US and the EU in 2010. CASHFLOW AND LIQUIDITY Shire's robust balance sheet includes ...

Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C

...ollowing the end of treatment). About Albinterferon Alfa-2b (Albuferon) Albinterferon alfa-2b is a novel, longer-acting form of interferon alfa that was created using the proprietary HGS albumin-fusion technology. Human albumin is the most prevalent naturally occurring blood protein in the hu...

Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C

...tment group. About Albinterferon Alfa-2b (Albuferon) Albinterferon alfa-2b is a novel, longer-acting form of interferon alfa that was created using the proprietary HGS albumin-fusion technology. Human albumin is the most prevalent naturally occurring blood protein in the hu...

EMD Serono Launches Landmark Patient Registry for Egg Freezing

... (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f(R) (follitropin alpha for injection), Luveris(R) (lutropin alfa for injection) and Ovidrel(R) Prefilled Syringe (choriogonadotropin alpha injection). With a clear focus on the patient and a leadership presence in t...

More>>

Other Tags
(Date:11/26/2014)... Santa Rosa, California (PRWEB) November 26, 2014 ... be making never before seen reductions in prices of ... and Liposomal Vitamin D3 . Discounts ... only. , GI for Life’s proprietary ColoVite ... leading board-certified gastroenterologists to promote colon health. One easy-to-take ...
(Date:11/26/2014)... IL (PRWEB) November 26, 2014 ... communication management solutions, has been award the ... Magazine. , This award comes as a great ... capabilities within the Lync ecosystem. Specifically, ISI offers ... all modes of Lync communication, including voice, video, ...
(Date:11/26/2014)... November 26, 2014 Medical suction and ... out of 5. This score represents steady growth in ... years to 2014 as a result of swelling demand ... machines, which are largely considered nondiscretionary. IBISWorld market research ... buyers have some degree of flexibility, given the low ...
(Date:11/26/2014)... Baton Rouge, Louisiana (PRWEB) November 26, 2014 ... and neck pain relief and specialists in minimally ... Dr. K. Samer Shamieh into the rapidly growing ... management specialists. The addition coincides with the ... cutting-edge, reliable medical treatment for Louisiana residents who ...
(Date:11/26/2014)... One of the most important and vital decisions a ... is choosing the ideal wedding dress and bridesmaid dresses. ... high quality outfits. Today, BellasDress.com has unveiled its new ... their suitable bridesmaid gowns here at discount prices. , ... scintillating and highlight all their most beautiful features while ...
Breaking Medicine News(10 mins):Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Royal Blue Bridesmaid Dresses Now Are Available for Christmas at BellasDress.com 2
(Date:11/21/2014)... Strict laws against distracted driving and the ... American and European automotive sector towards gesture recognition technologies. ... that are intuitive and able to retrieve information with ... New analysis from Frost & Sullivan,s Strategic ... Europe and North America ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
(Date:11/10/2014)... store shelves in early 2010, and people have used ... can be tossed into a washing machine without ever ... convenience, though, has come with risks for young children. ... Hospital found that from 2012 through 2013, U.S. poison ... 6 years of age swallowing, inhaling, or otherwise being ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2
Other Contents